Meera Mohan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Meera Mohan has a total of 435 co-authors. Here are the top co-authors by number of shared publications:
- Carolina Schinke
Myeloma Center, University of Arkansas for Medical Science, Little Rock, USA
23 shared publications - Binod Dhakal
Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, USA
21 shared publications - Anita D. Souza
Department of Medicine, Division of Hematology and Oncology Medical College of Wisconsin Milwaukee Wisconsin USA
20 shared publications - Aniko Szabo
Medical College of Wisconsin
18 shared publications - Frits van Rhee
Myeloma Center, University of Arkansas for Medical Science, Little Rock, USA
13 shared publications - Samer Al Hadidi
Myeloma, Waldenstrom’s, and Amyloidosis Program, Section of Hematologic Malignancies and Cellular Therapy, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas (S.A.H.).
12 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Blood Neoplasia
Circulating Multiple Myeloma Cell Kinetics and Genomic Profiling Predict Resistance to Targeted Immunotherapies
- 4 November 2026
- Published by Elsevier in Blood Neoplasia
Open AccessCirculating Multiple Myeloma Cell Kinetics and Genomic Profiling Predict Resistance to Targeted Immunotherapies
- Open Access
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis
Background: Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM). Methods: Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients receiving commercial cilta‐cel from March 2022 to December 2023. Frailty was defined by an adapted simplified score incorporating age, performance status, and comorbidities. Results: Among 541 patients with available frailty status, 183 (33.8%) were frail and 358 (66.2%) were nonfrail. Overall response rates were comparable (frail 82.8% vs. nonfrail 88.5%). However, frail patients had inferior progression‐free survival (PFS) (12‐month PFS, 62.7% [95% confidence interval (CI), 53.6%–71.3%] vs. 75.9% [95% CI, 70.4%–81.1%]; p < .01) and overall survival (OS) (12‐month OS 72.8% [95% CI, 64.9%–80.0%] vs. 90.4% [95% CI, 86.6%–93.7%]; p < .01). Twelve‐month treatment‐related mortality in frail patients was 6.8% (95% CI, 3.4%–11.2%) versus 3.6% (95% CI, 1.8%–6.1%), p = .12. Cytokine release syndrome (grade ≥2) occurred in 22.4% of frail versus 17.9% of nonfrail patients ( p = .05), and immune effector cell–associated neurotoxicity (ICANS) of any grade was reported in 32.2% versus 17.6% ( p < .01). Rates of cranial nerve palsies and Parkinsonism were comparable. Prolonged cytopenia (>day 30) was more common in frail patients (30.6% vs. 21.2%; p < .01). On multivariable analysis, frailty independently predicted worse PFS (hazard ratio [HR], 1.67; 95% CI, 1.16–2.40), OS (HR, 2.46; 95% CI, 1.57–3.87), and higher odds of any‐grade ICANS (odds ratio, 2.01; 95% CI, 1.32–3.08) (all p < .01). Conclusions: Cilta‐cel remains effective in frail RRMM, but frailty is associated with reduced survival and increased toxicity, supporting tailored CAR‐T strategies.
Open AccessEfficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis
Background: Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM). Methods: Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients receiving commercial cilta‐cel from March 2022 to December 2023. Frailty was defined by an adapted simplified score incorporating age, performance status, and comorbidities. Results: Among 541 patients with available frailty status, 183 (33.8%) were frail and 358 (66.2%) were nonfrail. Overall response rates were comparable (frail 82.8% vs. nonfrail 88.5%). However, frail patients had inferior progression‐free survival (PFS) (12‐month PFS, 62.7% [95% confidence interval (CI), 53.6%–71.3%] vs. 75.9% [95% CI, 70.4%–81.1%]; p < .01) and overall survival (OS) (12‐month OS 72.8% [95% CI, 64.9%–80.0%] vs. 90.4% [95% CI, 86.6%–93.7%]; p < .01). Twelve‐month treatment‐related mortality in frail patients was 6.8% (95% CI, 3.4%–11.2%) versus 3.6% (95% CI, 1.8%–6.1%), p = .12. Cytokine release syndrome (grade ≥2) occurred in 22.4% of frail versus 17.9% of nonfrail patients ( p = .05), and immune effector cell–associated neurotoxicity (ICANS) of any grade was reported in 32.2% versus 17.6% ( p < .01). Rates of cranial nerve palsies and Parkinsonism were comparable. Prolonged cytopenia (>day 30) was more common in frail patients (30.6% vs. 21.2%; p < .01). On multivariable analysis, frailty independently predicted worse PFS (hazard ratio [HR], 1.67; 95% CI, 1.16–2.40), OS (HR, 2.46; 95% CI, 1.57–3.87), and higher odds of any‐grade ICANS (odds ratio, 2.01; 95% CI, 1.32–3.08) (all p < .01). Conclusions: Cilta‐cel remains effective in frail RRMM, but frailty is associated with reduced survival and increased toxicity, supporting tailored CAR‐T strategies.
- Open Access
- 31 August 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 145
Correction: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
- 31 August 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1) , 145
Open AccessCorrection: Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
- Open Access
- 7 June 2026
- Published by Wiley in HemaSphere
- Vol. 10 (6) , e70396
Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
- 7 June 2026
- Published by Wiley in HemaSphere
- Vol. 10 (6) , e70396
Open AccessSustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
- 30 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (8) , 2028-2032
The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population‐Based Analysis
- 30 April 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (8) , 2028-2032
The Association of Age and Frailty With Adverse Events for Bortezomib and Carfilzomib: A Population‐Based Analysis
- Open Access
- 14 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications. Among 595 patients, median age was 64 years, 57% were male, and 70% had ≥1 comorbidity. Extramedullary disease and marrow plasma cell burden ≥ 50% were present in 13% and 14% of patients, respectively. The median number of prior lines of therapy was 7 and 8% had received prior BCMA-directed therapy. Median follow-up was 12 months (range, 1–25 months). Cytokine release syndrome occurred in 80% (≥ grade 3: 4%) and immune effector cell–associated neurotoxicity syndrome (ICANS) in 22% (≥ grade 3: 4%). Non-ICANS neurotoxicity was seen in 5% (n = 31), including Parkinsonism in 2.7% (n = 16) and cranial nerve palsies in 2.5% (n = 15), primarily cranial nerve VII (n = 12/15). Infections occurred in 47% and treatment-related mortality was 5%. The best overall response rate was 87%, with ≥ very good partial response rate in 75%, and ≥ complete response rate in 35%. Estimated 12-month progression-free and overall survival were 73% (95% CI: 68–77%) and 85% (95% CI: 81–88%), respectively. This represents the largest standard-of-care (SOC) study of cilta-cel in RRMM patients to date. Despite advanced disease and high comorbidity burden, cilta-cel demonstrated favorable safety and efficacy, supporting its use in clinical practice.
- 14 April 2026
- Published by Springer Nature in Blood Cancer Journal
- Vol. 16 (1)
Open AccessSafety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study
Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications. Among 595 patients, median age was 64 years, 57% were male, and 70% had ≥1 comorbidity. Extramedullary disease and marrow plasma cell burden ≥ 50% were present in 13% and 14% of patients, respectively. The median number of prior lines of therapy was 7 and 8% had received prior BCMA-directed therapy. Median follow-up was 12 months (range, 1–25 months). Cytokine release syndrome occurred in 80% (≥ grade 3: 4%) and immune effector cell–associated neurotoxicity syndrome (ICANS) in 22% (≥ grade 3: 4%). Non-ICANS neurotoxicity was seen in 5% (n = 31), including Parkinsonism in 2.7% (n = 16) and cranial nerve palsies in 2.5% (n = 15), primarily cranial nerve VII (n = 12/15). Infections occurred in 47% and treatment-related mortality was 5%. The best overall response rate was 87%, with ≥ very good partial response rate in 75%, and ≥ complete response rate in 35%. Estimated 12-month progression-free and overall survival were 73% (95% CI: 68–77%) and 85% (95% CI: 81–88%), respectively. This represents the largest standard-of-care (SOC) study of cilta-cel in RRMM patients to date. Despite advanced disease and high comorbidity burden, cilta-cel demonstrated favorable safety and efficacy, supporting its use in clinical practice.
Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Background: This first‐in‐human phase 1 study evaluated the B‐cell maturation antigen (BCMA)×CD3 bispecific antibody WVT078 alone and in combination with the γ‐secretase inhibitor WHG626 in patients with relapsed/refractory multiple myeloma (r/r MM). Method: The primary objectives were to assess safety, tolerability, and to determine the recommended doses (RDs) and regimens for expansion for WVT078 and WHG626. Secondary objectives included the assessment of preliminary antitumor activity and characterization of pharmacokinetics and immunogenicity. Result: Overall, 56 patients were treated in the dose‐escalation part of the study, seven of whom experienced dose‐limiting toxicities. Across all dose levels, cytokine release syndrome was the most common treatment‐related adverse event. WVT078 monotherapy showed an overall response rate (ORR) of 27.3% and a complete response rate (CRR) of 12.1%. WVT078 combined with WHG626 demonstrated an ORR of 47.8% and a CRR of 21.7%. RDs were not declared, and dose expansion was not initiated. Conclusion: WVT078 administered with and without WHG626 showed a manageable safety profile. Preliminary activity was observed in patients with r/r MM. The addition of WHG626 numerically improved response over WVT078 monotherapy. Findings from this study support further evaluation of WHG626 as a combination partner of BCMA‐targeting agents for r/r MM treatment.
Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Background: This first‐in‐human phase 1 study evaluated the B‐cell maturation antigen (BCMA)×CD3 bispecific antibody WVT078 alone and in combination with the γ‐secretase inhibitor WHG626 in patients with relapsed/refractory multiple myeloma (r/r MM). Method: The primary objectives were to assess safety, tolerability, and to determine the recommended doses (RDs) and regimens for expansion for WVT078 and WHG626. Secondary objectives included the assessment of preliminary antitumor activity and characterization of pharmacokinetics and immunogenicity. Result: Overall, 56 patients were treated in the dose‐escalation part of the study, seven of whom experienced dose‐limiting toxicities. Across all dose levels, cytokine release syndrome was the most common treatment‐related adverse event. WVT078 monotherapy showed an overall response rate (ORR) of 27.3% and a complete response rate (CRR) of 12.1%. WVT078 combined with WHG626 demonstrated an ORR of 47.8% and a CRR of 21.7%. RDs were not declared, and dose expansion was not initiated. Conclusion: WVT078 administered with and without WHG626 showed a manageable safety profile. Preliminary activity was observed in patients with r/r MM. The addition of WHG626 numerically improved response over WVT078 monotherapy. Findings from this study support further evaluation of WHG626 as a combination partner of BCMA‐targeting agents for r/r MM treatment.
- 9 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (5) , 1836-1840
Changes in patient‐reported distress and symptom burden during talquetamab therapy in multiple myeloma
- 9 March 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (5) , 1836-1840
Changes in patient‐reported distress and symptom burden during talquetamab therapy in multiple myeloma
- Open Access
- 17 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1400-1404
Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability
Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P< .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P< .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.
- 17 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1400-1404
Open AccessPlasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability
Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P< .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P< .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.